Matrix metalloproteinase inhibition attenuates right ventricular dysfunction and improves responses to dobutamine during acute pulmonary thromboembolism

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 12, 2013, Pages 1588-1597

  Neto Neves, Evandro M ^a   Sousa Santos, Ozelia ^a   Ferraz, Karina C ^b   Rizzi, Elen ^a   Ceron, Carla S ^a   Romano, Minna M D ^a   Gali, Luis G ^a   Maciel, Benedito C ^a   Schulz, Richard ^c   Gerlach, Raquel F ^a   Tanus Santos, Jose E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cardiomyocyte injury; Doxycycline; Matrix metalloproteinases; Pulmonary hypertension; Pulmonary thromboembolism; Right ventricular dysfunction

Indexed keywords

ANIMALIA; OVIS ARIES;

DOBUTAMINE; DOXYCYCLINE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; TROPONIN I;

ACUTE DISEASE; ANIMAL; ARTICLE; BLOOD; BLOOD PRESSURE; CARDIOMYOCYTE INJURY; DRUG EFFECT; HEART MUSCLE CELL; HEART OUTPUT; HEART RIGHT VENTRICLE FUNCTION; HEART VENTRICLE; LUNG EMBOLISM; MALE; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PULMONARY HYPERTENSION; RIGHT VENTRICULAR DYSFUNCTION; SHEEP; VASCULAR RESISTANCE; VASODILATATION;

CARDIOMYOCYTE INJURY; DOXYCYCLINE; MATRIX METALLOPROTEINASES; PULMONARY HYPERTENSION; PULMONARY THROMBOEMBOLISM; RIGHT VENTRICULAR DYSFUNCTION;

ACUTE DISEASE; ANIMALS; BLOOD PRESSURE; CARDIAC OUTPUT; DOBUTAMINE; DOXYCYCLINE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HEART VENTRICLES; HYPERTENSION, PULMONARY; MALE; MATRIX METALLOPROTEINASE INHIBITORS; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PULMONARY EMBOLISM; SHEEP; TROPONIN I; VASCULAR RESISTANCE; VASODILATION; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 84891151755     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12163     Document Type: Article

References (42)

1. Stratmann G, Gregory GA. Neurogenic and humoral vasoconstriction in acute pulmonary thromboembolism. Anesth Analg. 2003; 97: 341-54.
2. Piazza G, Goldhaber SZ. Fibrinolysis for acute pulmonary embolism. Vasc Med. 2010; 15: 419-28.
3. Wood KE. Major pulmonary embolism. Crit Care Clin. 2011; 27: 885-906, vi-vii.
4. Sanchez O, Trinquart L, Colombet I, et al. Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. Eur Heart J. 2008; 29: 1569-77.
5. Muller AL, Dhalla NS. Role of various proteases in cardiac remodeling and progression of heart failure. Heart Fail Rev. 2012; 17: 395-409.
6. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007; 87: 1285-342.
7. Ali MA, Fan X, Schulz R. Cardiac sarcomeric proteins: novel intracellular targets of matrix metalloproteinase-2 in heart disease. Trends Cardiovasc Med. 2011; 21: 112-8.
8. Kandasamy AD, Chow AK, Ali MA, et al. Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res. 2010; 85: 413-23.
9. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol. 2007; 47: 211-42.
10. Wang W, Schulze CJ, Suarez-Pinzon WL, et al. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation. 2002; 106: 1543-9.
11. Sawicki G, Leon H, Sawicka J, et al. Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation. 2005; 112: 544-52.
12. Sung MM, Schulz CG, Wang W, et al. Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury. J Mol Cell Cardiol. 2007; 43: 429-36.
13. Ali MA, Cho WJ, Hudson B, et al. Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury. Circulation. 2010; 122: 2039-47.
14. Neto-Neves EM, Dias-Junior CA, Rizzi E, et al. Metalloproteinase inhibition protects against cardiomyocyte injury during experimental acute pulmonary thromboembolism. Crit Care Med. 2011; 39: 349-56.
15. Layish DT, Tapson VF. Pharmacologic hemodynamic support in massive pulmonary embolism. Chest. 1997; 111: 218-24.
16. Westphal M, Rehberg S, Maybauer MO, et al. Cardiopulmonary effects of low-dose arginine vasopressin in ovine acute lung injury. Crit Care Med. 2011; 39: 357-63.
17. Neto-Neves EM, Dias-Junior CA, Uzuelli JA, et al. Sildenafil improves the beneficial hemodynamic effects exerted by atorvastatin during acute pulmonary thromboembolism. Eur J Pharmacol. 2011; 670: 554-60.
18. Dias-Junior CA, Gladwin MT, Tanus-Santos JE. Low-dose intravenous nitrite improves hemodynamics in a canine model of acute pulmonary thromboembolism. Free Radic Biol Med. 2006; 41: 1764-70.
19. Fortuna GM, Figueiredo-Lopes L, Dias-Junior CA, et al. A role for matrix metalloproteinase-9 in the hemodynamic changes following acute pulmonary embolism. Int J Cardiol. 2007; 114: 22-7.
20. Sousa-Santos O, Neto-Neves EM, Ferraz KC, et al. Antioxidant treatment protects against matrix metalloproteinase activation and cardiomyocyte injury during acute pulmonary thromboembolism. Naunyn Schmiedebergs Arch Pharmacol. 2012; 385: 685-96.
21. Ferraz KC, Sousa-Santos O, Neto-Neves EM, et al. Recombinant human matrix metalloproteinase-2 impairs cardiovascular beta-adrenergic responses. Basic Clin Pharmacol Toxicol. 2013; 112: 103-9.
22. Rizzi E, Castro MM, Ceron CS, et al. Tempol inhibits TGF-beta and MMPs upregulation and prevents cardiac hypertensive changes. Int J Cardiol. 2013; 165: 165-73.
23. Cheung PY, Sawicki G, Wozniak M, et al. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation. 2000; 101: 1833-9.
24. Binder L, Pieske B, Olschewski M, et al. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation. 2005; 112: 1573-9.
25. Kucher N, Goldhaber SZ. Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation. 2003; 108: 2191-4.
26. Uzuelli JA, Dias-Junior CA, Tanus-Santos JE. Severity dependent increases in circulating cardiac troponin I and MMP-9 concentrations after experimental acute pulmonary thromboembolism. Clin Chim Acta. 2008; 388: 184-8.
27. Cau SB, Barato RC, Celes MR, et al. Doxycycline prevents acute pulmonary embolism-induced mortality and right ventricular deformation in rats. Cardiovasc Drugs Ther. 2013; 27: 259-67.
28. Greyson CR. Right heart failure in the intensive care unit. Curr Opin Crit Care. 2012; 18: 424-31.
29. Greyson C, Xu Y, Lu L, et al. Right ventricular pressure and dilation during pressure overload determine dysfunction after pressure overload. Am J Physiol Heart Circ Physiol. 2000; 278: H1414-20.
30. Lualdi JC, Goldhaber SZ. Right ventricular dysfunction after acute pulmonary embolism: pathophysiologic factors, detection, and therapeutic implications. Am Heart J. 1995; 130: 1276-82.
31. Watts JA, Gellar MA, Obraztsova M, et al. Role of inflammation in right ventricular damage and repair following experimental pulmonary embolism in rats. Int J Exp Pathol. 2008; 89: 389-99.
32. Watts JA, Zagorski J, Gellar MA, et al. Cardiac inflammation contributes to right ventricular dysfunction following experimental pulmonary embolism in rats. J Mol Cell Cardiol. 2006; 41: 296-307.
33. Watts JA, Gellar MA, Stuart LK, et al. Proinflammatory events in right ventricular damage during pulmonary embolism: effects of treatment with ketorolac in rats. J Cardiovasc Pharmacol. 2009; 54: 246-52.
34. Orde MM, Puranik R, Morrow PL, et al. Myocardial pathology in pulmonary thromboembolism. Heart. 2011; 97: 1695-9.
35. Iwadate K, Doi M, Tanno K, et al. Right ventricular damage due to pulmonary embolism: examination of the number of infiltrating macrophages. Forensic Sci Int. 2003; 134: 147-53.
36. Grommes J, Soehnlein O. Contribution of neutrophils to acute lung injury. Mol Med. 2011; 17: 293-307.
37. Souza-Costa DC, Figueiredo-Lopes L, Alves-Filho JC, et al. Protective effects of atorvastatin in rat models of acute pulmonary embolism: involvement of matrix metalloproteinase-9. Crit Care Med. 2007; 35: 239-45.
38. Zagorski J, Gellar MA, Obraztsova M, et al. Inhibition of CINC-1 decreases right ventricular damage caused by experimental pulmonary embolism in rats. J Immunol. 2007; 179: 7820-6.
39. Viappiani S, Nicolescu AC, Holt A, et al. Activation and modulation of 72 kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochem Pharmacol. 2009; 77: 826-34.
40. Castro MM, Rizzi E, Ceron CS, et al. Doxycycline ameliorates 2K-1C hypertension-induced vascular dysfunction in rats by attenuating oxidative stress and improving nitric oxide bioavailability. Nitric Oxide. 2012; 26: 162-8.
41. Neto-Neves EM, Kiss T, Muhl D, et al. Matrix metalloproteinases as drug targets in acute pulmonary embolism. Curr Drug Targets. 2013; 14: 344-52.
42. Sertorio JT, Neto-Neves EM, Dias-Junior CA, et al. Elevated plasma hemoglobin levels increase nitric oxide consumption in experimental and clinical acute pulmonary thromboembolism. Crit Care Med. 2013; 41: e118-24.